Memorandum to the File: Regulatory Decision to Withdraw Avastin (bevacizumab) First-line Metastatic Breast Cancer Indication (BLA 125085) (2010)

Government Record · Richard Pazdur, Office of Oncology Drug Products, FDA CDER · December 15, 2010

Richard Pazdur et al., 2010-12-15: CDER office-director memo recommending withdrawal of the metastatic breast cancer indication granted under accelerated approval in February 2008, after AVADO and RIBBON1 failed to confirm the E2100 progression-free survival effect. It lists the other Avastin approvals then in force: colorectal, NSCLC, renal cell, glioblastoma.

The modest benefit observed with Avastin together with the substantial adverse reactions observed in breast cancer trials to date fail to provide a favorable risk-benefit profile to support continued marketing of Avastin for a first-line metastatic breast cancer indication.

p. 2

Richard Pazdur et al., 2010-12-15: CDER office-director memo recommending withdrawal of the metastatic breast cancer indication granted under accelerated approval in February 2008, after AVADO and RIBBON1 failed to confirm the E2100 progression-free survival effect. It lists the other Avastin approvals then in force: colorectal, NSCLC, renal cell, glioblastoma. Direct PDF verified (content-type application/pdf). Government document; no funder or COI. This is the 2010 proposal, not the final decision – the Commissioner's final order came on 18 November 2011 (CHC-09). Companion: FDA's 69-page Commissioner's opinion referenced in the press release. Study type: regulatory record.